Highlights Moderna, Inc.

Stocks

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/06/2026 am IST			After hours 05:30:00 am
61.80 ^USD	+11.55%		62.50	+1.13%

18/06	US Equity Indexes Drop as Bets for Higher Interest Rates Jump After Fed Eliminates Easing Bias	MT
18/06	US Equity Markets End Lower After Government Bond Yields Rise, Fed's Policy Statement	MT

Highlights

17/06	Moderna Plans Multiple Product Launches in 2027 and 2028	CI
16/06	Moderna announces executive changes ahead of potential launches	RE
09/06	Moderna Receives UK Authorization to Evaluate Cancer Vaccine for Lynch Syndrome	MT
03/06	HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery	RE
21/05	Moderna's Experimental Flu Shot to Be Reviewed by FDA Panel in June	MT
21/05	Moderna's Experimental Flu Shot to be Reviewed by FDA Panel in June, Bloomberg Reports	MT
07/05	Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial	RE
02/05	Tranche Update on Moderna, Inc.'s Equity Buyback Plan announced on August 3, 2022.	CI
02/05	Moderna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
01/05	Moderna Maintains 2026 Revenue Growth Outlook as First-Quarter Results Beat Estimates	MT
01/05	Moderna, Inc. Provides Earnings Guidance for the Second Quarter and Reiterates Earnings Guidance for Full Year 2026	CI
01/05	Moderna Q1 Loss Widens, Revenue Rises; Reiterates 2026 Revenue Outlook	MT
01/05	Earnings Flash (MRNA) Moderna Posts Q1 Loss $3.40 a Share, vs. FactSet Est of $4.45 Loss	MT
01/05	Moderna reports Q1 EPS of $ -3.40	RE
01/05	Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales	RE
01/05	Earnings Flash (MRNA) Moderna, Inc. Reports Q1 Revenue $389.0M, vs. FactSet Est of $236.4M	MT
01/05	Moderna tops revenue estimates on stronger international COVID vaccine sales	RE
27/04	Moderna Faces Fresh Patent Challenge From CureVac Over COVID Shot	MT
25/04	CureVac sues Moderna for patent infringement over COVID-19 vaccines	RE
21/04	Moderna receives European Commission marketing authorization for mCOMBRIAX	RE
21/04	Moderna Says European Commission Grants Marketing Authorization for mCombriax Vaccine for Influenza, COVID-19	MT
05/03	Moderna Shares Rise After Company Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT
04/03	Moderna to pay $950m to end litigation
04/03	Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang	RE
04/03	Moderna Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT